Athersys Total Assets 2011-2026 | ATHX

Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.

Main categories of assets
Current assets (used within one year):

Cash and cash equivalents
Accounts receivable (amounts owed by customers)
Inventory of goods, raw materials, and supplies
Short-term investments

Non-current assets (used for more than one year):

Fixed assets (buildings, machinery, equipment)
Intangible assets (brands, patents, software)
Long-term investments
Goodwill (reputational value from mergers)

Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.

Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.

Annual Total Assets Athersys

2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
60.2 M	59.7 M	41.7 M	61.7 M	33.6 M	19.1 M	25.1 M	28.7 M	34.2 M	27.6 M	15.7 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
61.7 M	15.7 M	37 M

Quarterly Total Assets Athersys

2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
7.43 M	10.5 M	21.6 M	27.7 M	35.5 M	35.2 M	45 M	60.2 M	72.1 M	73.3 M	72.3 M	59.7 M	59.7 M	59.7 M	59.7 M	41.7 M	41.7 M	41.7 M	41.7 M	61.7 M	61.7 M	61.7 M	61.7 M	33.6 M	33.6 M	33.6 M	33.6 M	19.1 M	19.1 M	19.1 M	19.1 M	25.1 M	25.1 M	25.1 M	25.1 M	28.7 M	28.7 M	28.7 M	28.7 M	34.2 M	34.2 M	34.2 M	34.2 M	27.6 M	27.6 M	27.6 M	27.6 M	15.7 M	15.7 M	15.7 M	15.7 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
73.3 M	7.43 M	36.3 M

Total Assets of other stocks in the Biotechnology industry

Issuer	Total Assets	Price	% 24h	Market Cap	Country
Assembly Biosciences ASMB	258 M	$ 28.46	3.45 %	$ 319 M	USA
Ascendis Pharma A/S ASND	1.3 B	$ 221.88	-0.87 %	$ 5 B	Danmark
MorphoSys AG MOR	2.03 B	-	2.43 %	$ 254 M	Germany
Axsome Therapeutics AXSM	690 M	$ 156.92	-1.23 %	$ 7.81 B	USA
Galera Therapeutics GRTX	7.2 M	-	-32.59 %	$ 7.61 M	USA
Pharming Group N.V. PHAR	215 M	$ 15.36	-0.71 %	$ 7.59 B	Niderland
Autolus Therapeutics plc AUTL	783 M	$ 1.37	-4.2 %	$ 350 M	Britain
Kamada Ltd. KMDA	379 M	$ 8.5	-1.39 %	$ 260 M	Israel
I-Mab IMAB	6.33 B	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	18.1 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	151 M	-	2.54 %	$ 160 B	France
Benitec Biopharma BNTC	99.6 M	$ 10.98	-4.52 %	$ 452 M	USA
Inventiva S.A. IVA	119 M	$ 5.78	-4.3 %	$ 138 M	France
Biophytis SA BPTS	12 M	-	-13.47 %	$ 169 M	France
Compugen Ltd. CGEN	157 M	$ 2.09	-0.95 %	$ 195 M	Israel
Tiziana Life Sciences PLC TLSA	11.3 M	$ 1.21	-3.97 %	$ 71.5 M	Britain
ARCA biopharma ABIO	396 M	-	1052.0 %	$ 415 M	USA
Midatech Pharma plc MTP	14.8 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	15.2 M	-	-1.52 %	$ 24.7 M	USA
Aeterna Zentaris AEZS	35.1 M	-	5.93 %	$ 314 M	Canada
Applied Genetic Technologies Corporation AGTC	66.7 M	-	-	$ 26.5 M	USA
PainReform Ltd. PRFX	4.52 M	$ 2.28	-0.44 %	$ 1.03 M	Israel
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
Acasti Pharma ACST	72 M	-	4.01 %	$ 150 M	Canada
Foghorn Therapeutics FHTX	198 M	$ 5.0	2.25 %	$ 315 M	USA
Институт стволовых клеток человека ISKJ	1.51 B	-	-	-	Russia
Adverum Biotechnologies ADVM	180 M	-	-	$ 86.2 M	USA
Acer Therapeutics ACER	11.6 M	-	2.71 %	$ 14 M	USA
Advaxis ADXS	16.6 M	-	-9.65 %	$ 45.9 M	USA
AbCellera Biologics ABCL	1.36 B	$ 3.4	-3.68 %	$ 1.02 B	Canada
BioMarin Pharmaceutical BMRN	7.59 B	$ 54.13	-1.64 %	$ 10.4 B	USA
Curis CRIS	41.3 M	$ 0.77	1.89 %	$ 4.86 M	USA
Bellerophon Therapeutics BLPH	7.94 M	-	-74.18 %	$ 955 K	USA
AgeX Therapeutics AGE	12 M	-	-10.17 %	$ 12.2 K	USA
Coherus BioSciences CHRS	258 M	$ 1.52	-5.59 %	$ 178 M	USA
Aeglea BioTherapeutics AGLE	778 M	-	-	$ 1.01 B	USA
CureVac N.V. CVAC	1.16 B	-	-	$ 867 M	Germany
Burford Capital Limited BUR	3.11 B	$ 7.7	-5.87 %	$ 1.29 B	Britain
Akero Therapeutics AKRO	826 M	-	-	$ 3.67 B	USA
Cellectis S.A. CLLS	325 M	$ 3.34	-4.02 %	$ 116 M	France
Arbutus Biopharma Corporation ABUS	144 M	$ 4.24	-2.97 %	$ 704 M	Canada
Akouos AKUS	279 M	-	0.23 %	$ 488 M	USA
Albireo Pharma ALBO	302 M	-	-0.23 %	$ 916 M	USA
AIkido Pharma AIKI	47.1 M	-	1.93 %	$ 17.4 M	USA
Cardiff Oncology CRDF	61.9 M	$ 1.8	-1.1 %	$ 120 M	USA
Allakos ALLK	244 M	-	-	$ 28.6 M	USA
Cabaletta Bio CABA	254 M	$ 2.94	-3.29 %	$ 3.43 M	USA
Iterum Therapeutics ITRM	44.6 M	$ 0.16	-5.45 %	$ 3.15 M	Irlanda
Brickell Biotech BBI	11.6 M	-	-5.38 %	$ 6.06 M	USA
Allena Pharmaceuticals ALNA	34.8 M	-	3.16 %	$ 1.9 M	USA